Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interplay of Central and Peripheral Vascular Effects of Insulin in Obesity
NCT07653464Phase 1Not yet recruiting
- Sponsor
- University of Missouri
- Start
- Dec 2026
- Primary completion
- Jun 2031
- Countries
- 1
01
Overview
Phase 1, open-label trial of Generex Oral-lyn in obesity and insulin resistance (IR) (2 arms), sponsored by University of Missouri. Primary endpoints: Muscle Sympathetic Nerve Activity at 30 months, Cerebral Blood Flow at 30 months and 1 more. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
Generex Oral-lyn
03
Conditions
obesityinsulin resistance (IR)
Beyond the preview
Go deeper on NCT07653464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07653464.